Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer

Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer

Blog Article

Ovarian cancer remains one of the most lethal gynecologic malignancies, primarily due 30x24x24 wall cabinet to late-stage diagnosis, high recurrence rates, and the development of chemoresistance.Although targeted therapies have improved patient outcomes, their efficacy is often limited by off-target toxicity and acquired drug resistance.Extracellular vesicles (EVs), nanoscale vesicles naturally released by cells, have emerged as promising carriers for precision drug delivery.

This review provides a comprehensive overview of recent advances in EV-based therapeutic strategies for ovarian cancer, including the delivery of chemotherapeutic agents, nucleic acid therapeutics, and immunomodulatory molecules.We further explore innovative engineering approaches to enhance targeting specificity, such as surface modification, cell source selection, biomaterial integration, and magnetic swisse high strength magnesium powder berry nanoparticle-assisted delivery.Key translational challenges in bringing EV-based therapies to clinical application are also addressed.

Collectively, these insights underscore the transformative potential of EV-based platforms in advancing targeted and personalized treatment for ovarian cancer.